Xoma | XOMA - Operating Profit


Xoma reported $-15.64M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Ardelyx USD 5.1M 431K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Curis USD -12.51M 40K Jun/2024
Eli Lilly USD 8.99B 599.9M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Incyte USD 383.88M 47.43M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Novartis USD 4.06B 521M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Prothena USD -27.21M 12.55M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024